In this concise communication, we shed some light on the urgent need to support and fund women’s sexual and reproductive health research in the area of STIs/HIV/unintended pregnancy prevention that is largely underserved. We stress the need for developing affordable safe and effective innovative vaginal products under the control of women to protect themselves against unintended pregnancy and sexually transmitted infections (STIs). We highlight the importance of complete and homogenous coverage of the vaginal and cervical mucosae of women by the vaginal product for optimal protection, especially against biofilm vaginal infections. Finally, we focus on the necessity of equity for women and the ease of access to such woman-controlled products for the benefit of the whole society.

Women’s health, Unintended pregnancy, Non-hormonal vaginal contraceptives, Sexually transmitted infections (STIs)/HIV, Multipurpose prevention technologies (MPTs), Health equity